ASCO 2016: Antibody drug conjugate shows early promise in small cell lung cancer
Early findings from a first-in-human clinical trial showed that antibody drug conjugate (ADC) rovalpituzumab tesirine…
Browsing: rovalpituzumab tesirine
Trending
- Making Telehealth Human – Podcast
- Sign Up for The Oncology Newsletter | Our free weekly news roundup
- The OJC Episode 23: ASCO GI Special
- Human pancreatic cancer model offers new opportunities for testing drugs
- Adding ipilimumab to pembrolizumab does not improve efficacy in patients with NSCLC
- Poor brain cancer survival outcomes on the rise
- Oesophageal cancer: 3-D printed stents deliver breakthrough treatment
- Potential therapeutic targets to inhibit colorectal cancer progression
- UK Lockdowns: Significant reduction in new cancer diagnoses
- More than half of cancer survivors have underlying medical conditions associated with severe COVID
